Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

High-Performance Calorimeter Enables Superior Materials Analysis and Development

By BiotechDaily International staff writers
Posted on 30 Apr 2013
Print article
Image: Shimadzu’s DSC-60 Plus series new differential scanning calorimeter (Photo courtesy of Shimadzu).
Image: Shimadzu’s DSC-60 Plus series new differential scanning calorimeter (Photo courtesy of Shimadzu).
A new, simple-to-operate, differential scanning calorimeter incorporates new technology designed to offer high sensitivity and resolution required for materials characterization in R&D and quality control applications for areas such as pharmaceuticals, polymers, etc.

Shimadzu (Kyoto, Japan) introduces their new thermal analyzer, the DSC-60 Plus series differential scanning calorimeter (DSC), for the analysis and development of high-performance, highly functional materials. In addition to top-class sensitivity and resolution, a new detector and a unique furnace construction achieve a noise level of less than 0.5 μW, providing a stable baseline from ultralow to high temperatures—across the entire measured temperature range (-140–600 °C). It also features a wide dynamic measurement range of ±150 mW (extended three times compared to previous Shimadzu instruments).

The DSC-60 Plus enables diverse and complex calorimetric measurements via simple operations. A cooling chamber with a liquid-nitrogen option permits easy measurements below room temperature (RT) - extremely convenient as it eliminates the need to install special accessories. A sample loading temperature function (SLTF) enables quick sample change during sequential analysis: while running a series of analyses below RT, the furnace temperature must be returned to near RT during sample replacement—the SLTF heats only the region around the sample when the sample is replaced, so that measurement can be rapidly resumed without moisture condensation.

The DSC-60 Plus is also eco-friendly. The newly designed furnace unit reduces energy consumption by over 20%, as measured when heating from RT to 300 °C at a 20 °C/minute heating rate (compared to previous Shimadzu instruments). When making measurements below RT, the liquid-nitrogen consumption savings exceed 30% (compared to previous Shimadzu instruments). The instrument footprint (W: 320 x H: 500 x D: 500 (mm)) has also been minimized.

The DSC-60 Plus series complies with various guidelines and regulations involving analytical laboratories, such as the PIC/S GMP guidelines, and electronic record/electronic signature (ER/ES) regulations and policies, including the US FDA 21 CFR Part11. In addition, it is compatible with various other analytical instruments and connected network systems, helping to ensure overall laboratory compliance.

Related Links:

Shimadzu



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.